News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center

Articles by Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center

Rapid Readouts: Phase 2 JULIET Trial

ByMatthew J. Frigault, MD, Massachusetts General Hospital Cancer Center

January 26th 2021

Ongoing Issues in CAR T-Cell Therapy and Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Developing CAR T-Cell Trials

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Allogenic CAR T-Cell Therapy in Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

CAR T-Cell Therapy’s Future for Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

CAR T Cells and Lymphoma Adverse Events

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

LBCL Therapy: The Right Therapy

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

R/R NHL: Candidate Identification and Referrals

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

CAR T-Cell Therapy for Follicular Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

ZUMA-2 Trial Overview: Mantle Cell Lymphoma Impact

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

LDH and ECOG Performance Tests

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Liso-cel Therapy in R/R Large B-Cell Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

The Importance of Antigen Loss in R/R Disease

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

R/R Large B-Cell Therapy in Managing Various Lymphomas

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

CAR T-Cell Therapy in Managing Various Lymphomas

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Rationale for Further Development of CAR T-Cell therapy

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Latest Updated Articles

Liso-cel Therapy in R/R Large B-Cell Lymphoma
Published: July 2nd 2020 | Updated:
LBCL Therapy: The Right Therapy
Published: July 2nd 2020 | Updated:
Rationale for Further Development of CAR T-Cell therapy
Published: July 2nd 2020 | Updated:
CAR T Cells and Lymphoma Adverse Events
Published: July 2nd 2020 | Updated:
CAR T-Cell Therapy’s Future for Lymphoma
Published: July 2nd 2020 | Updated:
R/R NHL: Candidate Identification and Referrals
Published: July 2nd 2020 | Updated:

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies